Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
RespireRx Pharmaceuticals Inc. (RSPI) generates news primarily through research, clinical development, regulatory and capital markets activities related to its neuromodulator and pharmaceutical cannabinoid programs. Through the RespireRx Group, which includes EndeavourRx LLC and ResolutionRx Ltd, the company reports progress on drug candidates targeting epilepsy, pain, attention deficit hyperactivity disorder (ADHD), recovery from spinal cord injury (SCI), certain neurological orphan diseases and obstructive sleep apnea (OSA).
News updates often highlight preclinical and translational findings for the company’s lead compounds. For example, RespireRx has reported peer-reviewed publications demonstrating that its AMPAkine CX1739 improved bladder function in rodent models of spinal cord injury and that KRM-II-81, its lead GABAkine, suppressed epileptiform activity in human brain tissue slices from a pharmaco-resistant epilepsy patient. Additional releases describe KRM-II-81’s advancement within the NIH HEAL Initiative Preclinical Screening Platform for Pain, where it has shown anti-pain effects in animal models at doses with minimal or no detectable side effects.
Investors and observers can also find announcements about external funding and collaborations, such as a Department of Defense translational research award to Shirley Ryan AbilityLab for a Phase 2A/2B clinical trial of CX1739 in SCI patients and an NIH/NINDS Small Business Innovation Research (SBIR) grant to support IND-enabling work for KRM-II-81 in epilepsy. Company communications further cover strategic steps at ResolutionRx Ltd to advance a new dronabinol formulation for OSA, including use of the Australian R&D Tax Incentive and plans for stock exchange listings.
Regulatory and corporate developments are another key theme in RSPI news. RespireRx has issued releases about SEC correspondence, the Section 12(j) order revoking registration of its securities, and its stated intention to pursue future Form 10 registration. Capital-raising initiatives, including a Regulation D, Rule 506(c) private placement across RespireRx, EndeavourRx and ResolutionRx, are also described. For ongoing context on RSPI, readers can review this news stream for updates on clinical plans, grant awards, licensing agreements, governance changes and the company’s responses to regulatory actions.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has established a wholly-owned subsidiary, ResolutionRx Ltd, in Australia to develop compounds targeting the endocannabinoid system, particularly dronabinol for obstructive sleep apnea (OSA). This initiative aims to leverage Australia’s research and development tax credit, potentially refunding 43.5% of eligible expenditures. ResolutionRx is pursuing equity financing and plans to list on the Australian Stock Exchange. The company is also collaborating with a contract research organization to conduct clinical studies on dronabinol, which has shown promise in earlier trials.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has been accepted into the NIH HEAL Initiative's NINDS Preclinical Screening Platform for Pain program. The company’s lead GABAkine, KRM-II-81, has shown potential in relieving acute, chronic, and neuropathic pain without common opioid-related side effects. KRM-II-81 has exhibited notable analgesic activity in preclinical studies, comparable to traditional analgesics. The initiative aims to advance solutions to the opioid crisis, highlighting the significance of RespireRx's innovative pain management approach.
RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) announced the signing of a letter of intent with an Australian clinical research organization on November 14, 2022. This LOI initiates a contract process for comprehensive CRO services related to clinical studies of dronabinol aimed at treating obstructive sleep apnea (OSA). The projected budget for the studies is about $17 million. The LOI may lead to the formation of an Australian subsidiary, ResolutionRx, to manage research activities and access funding options, including a tax credit program, though no assurances can be made regarding future financing.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announces Jeff Margolis, CFO, will present at the Investor Summit Q4 in New York on November 14, 2022. The event will feature a group presentation and individual meetings. RespireRx focuses on developing innovative treatments for psychiatric and neurological disorders, utilizing drug platforms including neuromodulators like AMPAkines and pharmaceutical cannabinoids. Their research targets ADHD, spinal cord injury, and obstructive sleep apnea, with a promising portfolio in clinical development.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced that Dr. Arnold Lippa, their Chief Scientific Officer, will speak at the 5th Meridian Drug Discovery Summit on November 7-8, 2022. He will present a talk on translational drug discovery and moderate a panel on diversity in drug discovery. The company focuses on treatments for neurological disorders, particularly ADHD, epilepsy, and obstructive sleep apnea, and is advancing drug candidates, including AMPAkines and GABAkines. Recent studies indicate promising clinical results for their lead compounds.
RespireRx Pharmaceuticals (OTCQ:RSPI) announced that Dr. Arnold Lippa, Executive Chairman and Chief Scientific Officer, will speak at the 5th International Cannabinoid-Derived Pharmaceuticals Summit from September 6-8, 2022, in Boston, MA. He will discuss the company's innovative lipid nanoparticle formulation technology aimed at repurposing dronabinol for obstructive sleep apnea (OSA) and other disorders. With over 29 million affected by OSA in the U.S., RespireRx is advancing clinical trials, including two Phase 2 studies showing promising results and plans for a Phase 3 study pending FDA discussions.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced that Dr. Arnold Lippa, Chief Scientific Officer, spoke at the 2022 GRI Virtual Conference on April 23. He presented data on the potential use of AMPAkines for treating GRI disorders, which include cognitive deficits and treatment-resistant seizures. Dr. Lippa highlighted positive results of AMPAkines in animal models simulating GRI disorders. The company's EndeavourRx unit is focused on developing these low-impact AMPAkines. RespireRx aims to collaborate with CureGRIN Foundation to advance treatments for GRI disorders.
RespireRx Pharmaceuticals (OTCQB:RSPI) announced the publication of a manuscript highlighting potential novel treatments for tinnitus, a disorder affecting 10-15% of the global population. The review by RespireRx scientists suggests that loss of GABA neurotransmission may contribute to tinnitus, with older GABAkines showing some symptom improvement despite side effects. The manuscript aims to energize the search for effective treatments. Additionally, RespireRx is developing KRM-II-81, a GABAkine, which may offer a game-changing solution for tinnitus patients.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the filing of a provisional patent application for a novel lipid-based formulation technology (LFT) to enhance the solubility and bioavailability of poorly soluble drugs, with a focus on cannabinoids. Their ResolutionRx unit is advancing dronabinol formulations for obstructive sleep apnea (OSA), having completed two Phase 2 trials showing significant symptom reduction. The company plans further testing pending financing. Improved formulations aim to expand market opportunities for dronabinol, including potential treatments beyond current approvals.
RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) announced the publication of a manuscript on D5-KRM-II-81, detailing its pharmacology. The study, led by Dr. Jeffrey M. Witkin, highlights the compound's ability to prevent seizures and its potential in treating pharmacoresistant epilepsy and pain. The findings support D5-KRM-II-81 as a promising orally-bioavailable option alongside KRM-II-81, which targets GABAA receptors. This advancement is crucial for addressing significant unmet medical needs in epilepsy and chronic pain treatment.